These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29308973)

  • 21. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
    Gao Q; Lei T; Ye F
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
    Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
    Park AK; Francis JM; Park WY; Park JO; Cho J
    Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Where now for anti-EGF receptor therapies in colorectal cancer?
    Shaw PH; Adams RA
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1543-53. PubMed ID: 21999128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor as a target for chemotherapy.
    Vallbohmer D; Lenz HJ
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
    Janmaat ML; Giaccone G
    Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the epidermal growth factor receptor in solid tumor malignancies.
    Nedergaard MK; Hedegaard CJ; Poulsen HS
    BioDrugs; 2012 Apr; 26(2):83-99. PubMed ID: 22385404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Directed therapies in lung cancer: new hope?
    Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
    Cohen RB
    Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers.
    Khan MH; Alam M; Yoo S
    Dermatol Surg; 2011 Sep; 37(9):1199-209. PubMed ID: 21615602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
    Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
    Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
    Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
    J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer.
    Scartozzi M; Pierantoni C; Berardi R; Antognoli S; Bearzi I; Cascinu S
    Anal Quant Cytol Histol; 2006 Apr; 28(2):61-8. PubMed ID: 16637508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
    Cohenuram M; Saif MW
    JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.